MPN Advocacy & Education International https://validator.w3.org/feed/docs/rss2.html Patient Stories: How I Manage My Chronic MPN Symptoms MPN Diagnoses in Adolescence and Young Adults Patient Stories: How the Lives of Two Mothers Changed with their Children’s MPN Diagnosis Patient Stories: Navigating Menopause and Postmenopause with an MPN Interferon Improves Myelofibrosis-Free Survival in AYA Patients with ET and PV Home Page Ruxolitinib Plus Siremadlin Yielded Superior Spleen Volume Reduction in Patients With Myelofibrosis Real-World Data Shows Favorable Efficacy and Safety With Busulfan for MPNs Engulfment Reduces Patient Quality of Life in MPNs GSK Fatigue, Quality of Life Improve With Rusfertide: Andrew Kuykendall, MD Prediction of resistance to hydroxyurea therapy in patients with polycythemia vera: a machine learning study (PV-AIM) validated in a prospective interventional phase IV trial (HU-F-AIM) As-Expected Ruxolitinib Starting Dose Outperforms Lower Dosage in Myelofibrosis Diagnosis and Management of PV and ET in Pediatric Populations Needs Improvement Assessing Risk for JAK Inhibitor Selection in Myelofibrosis Working to Address Unmet Medical Needs in MPNs How Essential Thrombocythemia and Polycythemia Vera Affect Blood Flow SVR With Pacritinib Is Linked With OS Benefit in Myelofibrosis With Thrombocytopenia Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling Post Hoc Data Show Anemia Benefits, Reduced Transfusion Burden With Momelotinib in Myelofibrosis Molecular Response to Therapy Linked With Event-Free Survival in PV 11th Annual Women & MPN Conference Defective neutrophil clearance in JAK2V617F myeloproliferative neoplasms drives myelofibrosis via immune checkpoint CD24 Interferon Lowers Myelofibrosis Risk in Young Patients With Polycythemia Vera, Essential Thrombocytopenia The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms Seiter Explores Time of Initiation and Alternate Dosing of Ruxolitinib in Myelofibrosis Fedratinib Shows Promise in Rare Myeloproliferative Neoplasms Silence Therapeutics Evolving Myelofibrosis Treatments Aims to Fill Unmet Needs News Leadership National Health Expenditure Associated With Myeloid Neoplasms Survival in Europe Biomed Valley Discoveries Announces First Patient Dosed in Phase 1/2 Combination Study of Ulixertinib with Ruxolitinib (Jakafi®) in Patients with Myelofibrosis Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF) Molecular predictors of venous and arterial thrombotic events in patients with myelofibrosis Conversation with an MPN Specialist: Dr. Kristen Pettit Online and In-Person Events Contact Us Management of common autoimmune diseases in patients with myeloproliferative neoplasms treated with pegylated interferon alfa—case report, review of the literature and multidisciplinary clinical practice recommendations Multihit TP53 Gene Mutations May Be Detrimental in MF Ruxolitinib Discontinuation at Conditioning Does Not Increase GVHD Risk in Myelofibrosis MOMENTUM Trial Outcomes: Guiding Therapy for Myelofibrosis With Anemia and Splenomegaly Strategic JAK Inhibitor Sequencing: Translating SIMPLIFY I/II Outcomes to Optimize Myelofibrosis Management FDA Grants Fast Track Designation to Givinostat for Polycythemia Vera QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025 Pegylated Interferons: Still a Major Player for the Treatment of Myeloproliferative Neoplasms Clinical Trial Aims to Test Tagraxofusp and Pacritinib Combination Therapy in Patients With MF Real-World Findings Confirm Clinical Data on Momelotinib in MF With Anemia